Alpha 2.0
Login Register
» Articles » PMID: 28984059

Treatment of Hepatitis C with 8 weeks of Ledipasvir/sofosbuvir: Highly Effective in a Predominantly Black Male Patient Population

Overview
Journal J Viral Hepat
Specialty Gastroenterology
Date 2017 Oct 7
PMID 28984059
Citations 2
Authors
L Tang
A Parker
Y Flores
M Dellario
C Dickson
A Amoroso
S Kottilil
E Wilson
Affiliations
Soon will be listed here.
Citing Articles

A simple, feasible, efficient and safe treatment strategy of sofosbuvir/velpatasvir for chronic HCV/HIV-1 coinfected patients regardless of HCV genotypes: a multicenter, open-label study in China.

Lin W, Wang X, Zhang J, Wen C, Kang W, Mao L Lancet Reg Health West Pac. 2023; 36:100749.

PMID: 37547041 PMC: 10398601. DOI: 10.1016/j.lanwpc.2023.100749.

A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY).

Wilson E, Covert E, Hoffmann J, Comstock E, Emmanuel B, Tang L J Hepatol. 2019; 71(3):498-504.

PMID: 31173815 PMC: 10885189. DOI: 10.1016/j.jhep.2019.05.021.